Ratings ContextVision AB

Equities

CONTX

SE0014731154

Market Closed - Oslo Bors Other stock markets 10:45:00 2024-05-06 am EDT			5-day change	1st Jan Change
6 ^NOK	0.00%		+0.33%	-22.08%

Apr. 03	ContextVision Announces New Image Quality Advancements in X-Ray	CI
Feb. 16	Transcript : ContextVision AB, Q4 2023 Earnings Call, Feb 16, 2024

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
The company has a poor ESG score according to Refinitiv, which ranks companies by sector.

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The group's high margin levels account for strong profits.
Thanks to a sound financial situation, the firm has significant leeway for investment.

Weaknesses

The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
With a 2024 P/E ratio at 25.97 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
The company is highly valued given the cash flows generated by its activity.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
CONTEXTVISION AB	-22.08%	42.85M		C-
VEEVA SYSTEMS INC.	+5.52%	32.83B		C
PRO MEDICUS LIMITED	+17.95%	7.73B		C-
SECTRA AB	+23.16%	3.96B		B-
EVOLENT HEALTH, INC.	-17.53%	3.12B		C-
OMNICELL, INC.	-20.33%	1.38B		B
LUNIT INC.	-30.65%	1.2B		-
SIMULATIONS PLUS, INC.	+7.73%	963M		C
B-SOFT CO.,LTD.	-33.44%	934M		-
VERADIGM INC.	-26.60%	829M	-	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes